To assess the efficacy and safety of Rotigotine transdermal patch (TP) in patients with Parkinson’s disease (PD). Methods: Articles were searched for involving randomized controlled trials (RCTs) of PD treatment using rotigotine TP that were published before November 11, 2020 on the CNKI, Wangfang, VIP, Sino Med, PubMed, Cochrane Library, and EMBASE databases. Data extraction and assessment of methodological bias of the RCTs were independently completed by 2 researchers. Meta-analysis of data was performed using Stata and RevMan software. Results: A total of 16 RCTs with 4 682 PD patients were enrolled. Rotigotine TP significantly reduced UPDRS-Ⅲ, UPDRS-Ⅱ, and UPDRS-(Ⅱ+Ⅲ) scores, indicating that the treatment led to a significant amelioration of movement symptoms and ADL limitations. Moreover, Rotigotine TP significantly reduced PDSS-2 scores, suggesting that it led to a remarkable improvement in sleep quality. Compared with placebo group subjects, patients taking Rotigotine TP did not experience a greater incidence of adverse events. Conclusion: The efficacy and safety of Rotigotine TP in treating PD were verified.